Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy

2008 ◽  
Vol 49 (5) ◽  
pp. 939-947 ◽  
Author(s):  
Timucin Cil ◽  
Abdullah Altintas ◽  
Semir Pasa ◽  
Kadim Bayan ◽  
Tuncer Ozekinci ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Cancer Patients ◽  
Surface Antigen ◽  
Hepatitis B Surface Antigen ◽  
Cytotoxic Chemotherapy ◽  
Virus Reactivation ◽  
Hepatitis B Virus Reactivation ◽  
B Virus

scholarly journals Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression

Hepatology ◽  
2015 ◽  
Vol 61 (3) ◽  
pp. 823-833 ◽  
Author(s):  
Romina Salpini ◽  
Luna Colagrossi ◽  
Maria Concetta Bellocchi ◽  
Matteo Surdo ◽  
Christina Becker ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Surface Antigen ◽  
Immune Escape ◽  
Hepatitis B Surface Antigen ◽  
Virus Reactivation ◽  
Hepatitis B Virus Reactivation ◽  
Genetic Elements ◽  
B Virus

Hepatitis B virus reactivation during combined therapy with deferiprone and desferioxamine in a hepatitis B surface antigen thalassemic carrier

2008 ◽  
Vol 89 (2) ◽  
pp. 135-138 ◽  
Author(s):  
Paolo Ricchi ◽  
Patrizia Cinque ◽  
Alfonso Lanza Galeota ◽  
Tiziana Di Matola ◽  
Massimiliano Ammirabile ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Surface Antigen ◽  
Hepatitis B Surface Antigen ◽  
Combined Therapy ◽  
Virus Reactivation ◽  
Hepatitis B Virus Reactivation ◽  
B Virus

Increased risk of hepatitis B virus reactivation in systemic lupus erythematosus patients receiving immunosuppressants: a retrospective cohort study

Lupus ◽  
2017 ◽  
Vol 27 (1) ◽  
pp. 66-75 ◽  
Author(s):  
W T Lin ◽  
Y M Chen ◽  
D Y Chen ◽  
J L Lan ◽  
C S Chang ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Surface Antigen ◽  
Lupus Erythematosus ◽  
Hepatitis B Surface Antigen ◽  
Virus Reactivation ◽  
Systemic Lupus ◽  
Hepatitis B Virus Reactivation ◽  
B Virus

Objective We aimed to investigate risk of hepatitis B virus reactivation in systemic lupus erythematosus patients with different hepatitis B virus infection statuses receiving immunosuppressive therapy. Methods We retrospectively analyzed systemic lupus erythematosus patients with positive hepatitis B surface antigen or anti-hepatitis B core IgG antibody who underwent immunosuppressive therapies from January 2001 to December 2012 at a medical center in Taiwan for evidence of hepatitis B virus reactivation. Results During this period, 906 out of 3125 patients who were diagnosed with systemic lupus erythematosus received screening tests for hepatitis B virus. Thirty-eight patients were identified as hepatitis B surface antigen-positive. Fifteen of 38 (39.5%) hepatitis B surface antigen-positive patients developed hepatitis B virus reactivation, and 53.3% of these patients experienced severe hepatitis flare. Three of 157 hepatitis B surface antigen-negative/anti-hepatitis B core IgG antibody-positive patients (1.9%) experienced hepatitis B surface antigen seroreversion after immunosuppressive therapy. Five patients received prophylactic or preemptive antiviral therapy and none of them developed hepatitis B virus flares. A daily dose of prednisolone greater than 5 mg was a risk factor for hepatitis B reactivation by multivariate logistic analysis. Conclusions The risk of hepatitis B virus reactivation is high in lupus patients receiving immunosuppressive therapy. Antiviral prophylaxis or preemption can effectively reduce the incidence of hepatitis B virus reactivation in lupus patients.

Sign in / Sign up

Export Citation Format

Share Document